Epstein-Barr Viral Infections - Pipeline Review, H2 2016

  • ID: 3837860
  • Drug Pipelines
  • 71 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Arno Therapeutics, Inc.
  • Cell Medica Limited
  • Genocea Biosciences, Inc.
  • Humabs BioMed SA
  • Molplex Ltd.
  • Omeros Corporation
  • MORE
Epstein-Barr Viral Infections - Pipeline Review, H2 2016

Summary

‘Epstein-Barr Viral Infections - Pipeline Review, H2 2016’, provides an overview of the Epstein-Barr Viral Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epstein-Barr Viral Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epstein-Barr Viral Infections and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epstein-Barr Viral Infections
- The report reviews pipeline therapeutics for Epstein-Barr Viral Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Epstein-Barr Viral Infections therapeutics and enlists all their major and minor projects
- The report assesses Epstein-Barr Viral Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Epstein-Barr Viral Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Epstein-Barr Viral Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Epstein-Barr Viral Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Arno Therapeutics, Inc.
  • Cell Medica Limited
  • Genocea Biosciences, Inc.
  • Humabs BioMed SA
  • Molplex Ltd.
  • Omeros Corporation
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Epstein-Barr Viral Infections Overview

Therapeutics Development

Pipeline Products for Epstein-Barr Viral Infections - Overview

Pipeline Products for Epstein-Barr Viral Infections - Comparative Analysis

Epstein-Barr Viral Infections - Therapeutics under Development by Companies

Epstein-Barr Viral Infections - Therapeutics under Investigation by Universities/Institutes

Epstein-Barr Viral Infections - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Epstein-Barr Viral Infections - Products under Development by Companies

Epstein-Barr Viral Infections - Products under Investigation by Universities/Institutes

Epstein-Barr Viral Infections - Companies Involved in Therapeutics Development

Arno Therapeutics, Inc.

Cell Medica Limited

Epiphany Biosciences, Inc.

Genocea Biosciences, Inc.

Humabs BioMed SA

Molplex Ltd.

Omeros Corporation

Savoy Pharmaceuticals, Inc.

Theravectys SA

Vironika, LLC

ViroStatics srl

Epstein-Barr Viral Infections - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AR-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for EBV Associated PTLD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Systemic Lupus Erythematosus and Epstein-Barr Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target Calcineurin A for EBV associated post transplant B cell lymphoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMD-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Epstein-Barr virus (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Epstein-Barr virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Epstein-Barr Viral Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MVA vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Infectious Mononucleosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit EBNA1 for Epstein-Barr Virus (EBV) Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target GPR183 for Osteoporosis and Epstein-Barr Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EBNA1 for Epstein-Barr Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Epstein-Barr Virus and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

valomaciclovir stearate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Viroprev - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Epstein-Barr Viral Infections - Dormant Projects

Epstein-Barr Viral Infections - Product Development Milestones

Featured News & Press Releases

Mar 25, 2014: University of Birmingham launches trial to fight cancer caused by a common virus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Epstein-Barr Viral Infections, H2 2016

Number of Products under Development for Epstein-Barr Viral Infections - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Epstein-Barr Viral Infections - Pipeline by Arno Therapeutics, Inc., H2 2016

Epstein-Barr Viral Infections - Pipeline by Cell Medica Limited, H2 2016

Epstein-Barr Viral Infections - Pipeline by Epiphany Biosciences, Inc., H2 2016

Epstein-Barr Viral Infections - Pipeline by Genocea Biosciences, Inc., H2 2016

Epstein-Barr Viral Infections - Pipeline by Humabs BioMed SA, H2 2016

Epstein-Barr Viral Infections - Pipeline by Molplex Ltd., H2 2016

Epstein-Barr Viral Infections - Pipeline by Omeros Corporation, H2 2016

Epstein-Barr Viral Infections - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016

Epstein-Barr Viral Infections - Pipeline by Theravectys SA, H2 2016

Epstein-Barr Viral Infections - Pipeline by Vironika, LLC, H2 2016

Epstein-Barr Viral Infections - Pipeline by ViroStatics srl, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Epstein-Barr Viral Infections - Dormant Projects, H2 2016 68List of Figures

Number of Products under Development for Epstein-Barr Viral Infections, H2 2016

Number of Products under Development for Epstein-Barr Viral Infections - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Arno Therapeutics, Inc.
  • Cell Medica Limited
  • Genocea Biosciences, Inc.
  • Humabs BioMed SA
  • Molplex Ltd.
  • Omeros Corporation
  • MORE
According to our recently published report 'Epstein-Barr Viral Infections – Pipeline Review, H2 2016'; Epstein-Barr Viral Infections pipeline therapeutics constitutes close to 24 molecules. Out of which approximately 11 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says: Epstein-Barr Viral Infections Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most common human viruses. EBV spreads most commonly through bodily fluids. EBV can also spread through blood and semen during sexual contact, blood transfusions, and organ transplantations. Symptoms of EBV infections include fatigue, fever, and inflamed throat, swollen lymph nodes in the neck, enlarged spleen, swollen liver and rash.

The report 'Epstein-Barr Viral Infections – Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Epstein-Barr Viral Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Epstein-Barr Viral Infections and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 5 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 4, 2 and 2 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
Arno Therapeutics, Inc.
Cell Medica Limited
Epiphany Biosciences, Inc.
Genocea Biosciences, Inc.
Humabs BioMed SA
Molplex Ltd.
Omeros Corporation
Savoy Pharmaceuticals, Inc.
Theravectys SA
Vironika, LLC
ViroStatics srl
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll